drugset / Trial / NCT01731951

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

NCT01731951

Phase 2 Completed 80 enrolled Geron Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2012-10-29
Primary completion
2018-05-24
Completion
2018-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Imetelstat Oligonucleotide (other) 7.5 mg/kg Intravenous
Subject Imetelstat Oligonucleotide (other) 9.4 mg/kg Intravenous